Glaukos Corp filed an 8-K to disclose the availability of its August 2026 Investor Presentation on its investor relations website. The filing contains no material operational updates, financial results, or corporate actions beyond directing investors to the presentation materials. Glaukos Corporation is a medical device and pharmaceutical company specializing in minimally invasive treatments for glaucoma, keratoconus, and other chronic eye diseases.

Glaukos Corporation reported second quarter 2026 financial results on July 29, 2026. The company achieved record net sales of $185.6 million, a 50% year-over-year increase, driven by strong performance in its glaucoma franchise which generated $155.2 million in sales. U.S. glaucoma sales rose 64% to $118.5 million, largely due to the adoption of iDose TR. The company raised its full-year 2026 net sales guidance to a range of $680 million to $700 million from the previous estimate of $620 million to $635 million. Glaukos reported a GAAP net loss of $18.4 million, or $0.31 per diluted share, compared to a net loss of $19.7 million in the prior year period. The company ended the quarter with approximately $289.3 million in cash and investments and no debt. Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company focused on novel therapies for glaucoma, corneal disorders, and retinal diseases.